Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Insmed Incorporated and Supernus Pharmaceuticals, Inc. have demonstrated contrasting strategies in optimizing these costs.

From 2014 to 2023, Supernus Pharmaceuticals consistently maintained a higher SG&A expense, peaking at approximately $377 million in 2022. This represents a staggering 420% increase from their 2014 expenses. In contrast, Insmed Incorporated's SG&A expenses grew by about 1,010% over the same period, reaching around $345 million in 2023.

While Supernus Pharmaceuticals appears to have a more stable growth trajectory, Insmed's rapid increase suggests aggressive expansion or investment in administrative capabilities. Understanding these trends provides valuable insights into each company's operational strategies and financial health.

As investors and analysts evaluate these companies, the ability to manage SG&A costs effectively remains a key indicator of future success.